Abstract: This invention is directed to a compound of formula (I): wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Abstract: This invention is directed to a compound of formula (I): wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.

Abstract: The present invention relates to a series of substituted aza-indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Abstract: The present invention relates to a series of substituted indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..

Abstract: A high speed DWDM optical transmission system that reduces a fiber dispersion limit without reducing the total channel count of a multi-wavelength optical signal. The system achieves such reduction in the fiber dispersion limit by employing a multi-wavelength optical signal comprising a gap-free band structure, and performing per-band dispersion compensation on the optical signal by adjusting residual dispersion values associated with one or more of the bands. In one embodiment, the system includes a first dispersion compensation module (DCM) that provides a dispersion-compensated multi-wavelength optical signal containing wavelength-dependent residual dispersion to a band splitter. The band splitter separates the dispersion-compensated optical signal into a plurality of bands such that no band gaps are formed between adjacent bands, and provides each band to a respective second DCM configured to reduce the residual dispersion associated with that band to a predetermined range of residual dispersion values.

Abstract: A high speed DWDM optical transmission system that reduces a fiber dispersion limit without reducing the total channel count of a multi-wavelength optical signal. The system achieves such reduction in the fiber dispersion limit by employing a multi-wavelength optical signal comprising a gap-free band structure, and performing per-band dispersion compensation on the optical signal by adjusting residual dispersion values associated with one or more of the bands. In one embodiment, the system includes a first dispersion compensation module (DCM) that provides a dispersion-compensated multi-wavelength optical signal containing wavelength-dependent residual dispersion to a band splitter. The band splitter separates the dispersion-compensated optical signal into a plurality of bands such that no band gaps are formed between adjacent bands, and provides each band to a respective second DCM configured to reduce the residual dispersion associated with that band to a predetermined range of residual dispersion values.